Sunesis Pharmaceuticals - Positive Phase 2 Daten! ( Seite 10)

Huhu ab geht er der Klaus Peter

Antwort auf Beitrag Nr.: 39.412.397 von ericcartman am 27.04.10 21:16:37Aber du meinst nicht mich - oder?

Tja, die Diskussion scheint hier irgendwie erloschen zu sein.

Schaut man sich das Chartbild von snss an, könnte demnächst mal wieder eine Trendumkehr/Rebound erfolgen. Meinungen?

07.06.2010 21:04
Sunesis Announces Data From Phase 2 Clinical Program of Voreloxin in Acute Myeloid Leukemia Support Phase 3 Trial in Relapsed or Refractory Patients / Updated, Positive Phase 2 Data in AML and Ovarian Cancer Presented at the ASCO 2010 Annual Meeting; Sun

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 06/07/10 -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced updated clinical data from Phase 2 clinical studies of the Company's lead drug candidate, voreloxin, in acute myeloid leukemia (AML) and platinum-resistant ovarian cancer. The results were presented today at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The presentations are available on the Sunesis website at www.sunesis.com.

Clinical data from the Sunesis' Phase 2 clinical trial of voreloxin in combination with cytarabine in first relapsed or primary refractory AML exhibit a meaningful improvement in overall survival relative to literature-based values reported for current treatment standards of care, including cytarabine-based regimens. These positive clinical findings, along with formal feedback from both U.S. and EU regulatory agencies, support Sunesis' plan to initiate a multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed/refractory AML patient population in the second half of this year.

"Across both AML studies, either as a single agent in frontline elderly AML or in combination with cytarabine in relapsed/refractory AML, voreloxin has consistently achieved clinically meaningful remission rates balanced with impressively low all-cause early mortality," said Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina and a clinical study investigator for both Phase 2 AML clinical trials. "There remains a significant and enduring unmet need for new therapies among patients with this disease. These results merit investigation in a larger outcome study in AML and I look forward to actively participating in Sunesis' planned Phase 3 clinical trial in relapsed/refractory AML."

"Data from these Phase 2 trials underscore voreloxin's potential as a treatment for both hematologic cancers and solid tumors," said Steven Ketchum, Ph.D., Senior Vice President of Research and Development at Sunesis. "In particular, in our Phase 2 trial of relapsed/refractory AML, voreloxin in combination with cytarabine has demonstrated impressive survival outcomes, leading us to focus our initial development and registration efforts on this patient population. Based on our substantial Phase 2 dataset, combined with our careful review of literature and input from clinical advisors and regulatory agencies, we are confident that our planned Phase 3 trial is rigorously designed to detect a significant difference in overall survival."

With 450 evaluable patients, the Phase 3 clinical trial will have 90% power to detect a 40% difference in overall survival. In this trial, there will be a single prespecified interim analysis by an independent Data Safety Monitoring Board (DSMB) which will enable the DSMB to implement a one-time sample size adjustment of 225 additional evaluable patients to maintain adequate power across a broader range of potential survival outcomes. Sunesis' ongoing focus is directed toward the initiation of this multinational pivotal Phase 3 trial later this year.

Phase 2 Clinical Trial of Voreloxin in Combination with Cytarabine in Relapsed/Refractory AML - Abstract #6526

In a poster presentation and poster discussion session, investigators presented data from a Phase 2 clinical trial testing voreloxin in combination with cytarabine, a widely used chemotherapy, in patients with relapsed or refractory AML. In this trial, a total of 69 patients with first relapse or primary refractory AML have been treated at doses of 80 to 90 mg/m2 of voreloxin, in addition to either bolus or continuous infusion cytarabine.

* Among evaluable first relapse (n=36) and primary refractory patients (n=33), median overall survival is 7.1 months. Of these patients, over 80% were either primary refractory or had an initial first remission (CR1) of less than 12 months. 20 patients are still in survival follow-up and are beyond the current median; 12 of these patients have survived out to one year or more as of the most recent evaluation.
* Preliminary median leukemia-free survival (LFS) is 10.8 months.
* The overall remission rate was 29% with the vast majority being complete remissions (17 of 20).
* Infection-related toxicities were the most common Grade 3 or higher non-hematologic adverse events, all of which were expected. In addition, Grade 3 or higher oral mucositis was observed. The combination of voreloxin and cytarabine, regardless of cytarabine schedule, did not appear to exacerbate mucositis.
* All-cause mortality among these patients was 3% at 30 days and 9% at 60 days.
* The dose regimen to be used in the pivotal Phase 3 trial is 90 mg/m2 of voreloxin given as a 10 minute infusion on days one and four and 1 g/m2 of bolus cytarabine given as a two hour infusion on days one through five.

Phase 2 Clinical Trial of Single Agent Voreloxin in Newly Diagnosed Elderly AML (REVEAL-1 Trial) - Abstract #6525

In a poster presentation and poster discussion session, investigators presented data from the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose optimization trial of single agent voreloxin in previously untreated, elderly AML patients who are unlikely to benefit from standard induction chemotherapy. 113 AML patients have been treated in the trial, 82 percent of whom had two or more adverse risk factors, including age greater than 70 and intermediate or unfavorable cytogenetics. Median age for patients in the trial was 74 years. The REVEAL-1 trial includes three dosing schedules. As previously reported, Schedule C (72 mg/m2 of voreloxin on days one and four) is the recommended dose regimen for further study.

* For Schedule C (72 mg/m2, n=30), median overall survival was 7.7 months and one year survival is approximately 38%, with 33% of patients remaining in follow-up. Response rate (CR and CRp) was 38%; 30- and 60-day all-cause mortality were 7% and 17%, respectively.
* The most common grade 3 or higher non-hematologic adverse events included upper GI mucosal inflammation and infection.

"For elderly AML patients that present with additional risk factors, options are often limited due to the patients' intolerance to standard treatment," said Farhad Ravandi, M.D., Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, and an investigator in the Phase 2 clinical trial. "Voreloxin has demonstrated both strong anti-leukemic activity and adequate tolerability in this population, a balance which has yielded encouraging survival outcomes. I look forward to seeing voreloxin developed further in this and other AML settings."

Phase 2 Clinical Trial of Single Agent Voreloxin in Women with Platinum-Resistant Ovarian Cancer - Abstract #5002

Final clinical data from the Phase 2 trial of single agent voreloxin in women with platinum-resistant ovarian cancer were also presented during an oral presentation at the ASCO 2010 Annual Meeting. Platinum resistance is defined as progression within six months of completing platinum-based chemotherapy or progression while on platinum-based chemotherapy. Patients may have received up to three prior platinum regimens plus one additional non-platinum cytotoxic regimen. For approximately one third of the patients studied, prior treatment with Doxil® had failed. A total of 143 patients were enrolled in the trial, and enrollment was completed in December of 2008. Three dose cohorts of voreloxin were studied, and the 60 mg/m2 of voreloxin given every four weeks used in Cohort B is the recommended dose regimen for further study.

* Data from this Phase 2 trial demonstrated encouraging, durable anti-tumor activity across all three dose cohorts, with the majority of patients achieving stable disease or an objective response.
* For Cohort B (n=37), 54% of patients achieved disease control including 11% objective response rate (ORR, 2 CRs and 2 PRs), low incidence of grade 3 or higher febrile neutropenia (16%) and a long progression-free survival, with one patient remaining on study after 26 cycles of voreloxin. Median progression-free survival (PFS) was 85 days.
* Four PRs were achieved in the 44 women who were Doxil® failures for an ORR of 9%. 66% of these patients achieved disease control, and median PFS in Doxil® failure patients was 91 days.
* Overall, the adverse event profile was similar across cohorts and voreloxin was generally well-tolerated. Grade 3 or higher adverse events occurring in more than 10% of patients included neutropenia, febrile neutropenia, and anemia, all of which were expected and reversible with standard care.

"Responses to single agent voreloxin observed in women with ovarian cancer for whom multiple prior therapies have failed, including some for whom both platinum-based chemotherapy and Doxil® had failed, are promising," said Hal Hirte, M.D., Associate Professor, McMaster University, Department of Oncology and Chief of Oncology, Juravinski Cancer Centre at Hamilton Health Sciences and an investigator for the Phase 2 clinical trial. "These data warrant further investigation of voreloxin in this vastly underserved patient population, both in this later stage, salvage setting and in earlier lines of therapy."

Conference Call Information

Sunesis will host a conference call and webcast slide presentation Tuesday, June 8th at 9:00 a.m. Eastern time. Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, will join the Sunesis senior management team in a discussion of the new Phase 2 data presented at ASCO and review the plans for the upcoming randomized, pivotal Phase 3 clinical trial evaluating the effect on overall survival of voreloxin in combination with cytarabine for the treatment of first relapsed or refractory AML. The call can be accessed by dialing (877) 303-9029 (U.S. and Canada) or (914) 495-8584 (international). To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on Sunesis' website for two weeks.

http://www.finanznachrichten.de/nachrichten-2010-06/17091480-sunesis-announces-data-from-phase-2-clinical-program-of-voreloxin-in-acute-myeloid-leukemia-support-phase-3-trial-in-relapsed-or-refractory-patients-256.htm

Upcoming Events

Jun 9, 2010
10:40 AM ET 9th Annual Needham Healthcare Conference
Speaker: Daniel Swisher, Chief Executive Officer
Show Additional Information



New York Palace Hotel, New York City
Jun 10, 2010
8:00 AM ET Jefferies 2010 Global Life Sciences Conference
Speaker: Daniel Swisher, Chief Executive Officer of Sunesis
Webcast Listen to webcast
Show Additional Information
Reminder Remind me
Please sign up for email alert notification.



Grand Hyatt, New York City
Jun 16, 2010
11:30 AM ET ThinkEquity Mid Year Check-Up on Healthcare
Speaker: Daniel Swisher, Chief Executive Officer
Show Additional Information
Reminder Remind me

Antwort auf Beitrag Nr.: 39.659.248 von b@rca am 09.06.10 23:02:36Clinical data from the Sunesis' Phase 2 clinical trial of voreloxin in combination with cytarabine in first relapsed or primary refractory AML exhibit a meaningful improvement in overall survival relative to literature-based values reported for current treatment standards of care, including cytarabine-based regimens. These positive clinical findings, along with formal feedback from both U.S. and EU regulatory agencies, support Sunesis' plan to initiate a multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed/refractory AML patient population in the second half of this year.

Antwort auf Beitrag Nr.: 39.659.315 von b@rca am 09.06.10 23:16:50Noch offen:

Partnerschaft mit dem damit verbundenen
Start der 2 Phase 3 Studien.

Tja, die tun und machen doch der Kurs stürzt immer weiter ab.
Die Frage ist nur wann der Boden gefunden ist...